Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Profit After Tax: 2020-2024

Historic Profit After Tax for Monte Rosa Therapeutics (GLUE) over the last 5 years, with Dec 2024 value amounting to -$72.7 million.

  • Monte Rosa Therapeutics' Profit After Tax fell 13.50% to -$27.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.9 million, marking a year-over-year increase of 117.54%. This contributed to the annual value of -$72.7 million for FY2024, which is 46.31% up from last year.
  • According to the latest figures from FY2024, Monte Rosa Therapeutics' Profit After Tax is -$72.7 million, which was up 46.31% from -$135.4 million recorded in FY2023.
  • In the past 5 years, Monte Rosa Therapeutics' Profit After Tax registered a high of -$35.9 million during FY2020, and its lowest value of -$135.4 million during FY2023.
  • For the 3-year period, Monte Rosa Therapeutics' Profit After Tax averaged around -$105.5 million, with its median value being -$108.5 million (2022).
  • Its Profit After Tax has fluctuated over the past 5 years, first tumbled by 106.13% in 2021, then skyrocketed by 46.31% in 2024.
  • Over the past 5 years, Monte Rosa Therapeutics' Profit After Tax (Yearly) stood at -$35.9 million in 2020, then slumped by 106.13% to -$74.0 million in 2021, then plummeted by 46.62% to -$108.5 million in 2022, then fell by 24.79% to -$135.4 million in 2023, then surged by 46.31% to -$72.7 million in 2024.